In this article, we will list the 5 Hidden Multibagger Stocks to Buy Right Now. Please read the article 8 Hidden Multibagger Stocks to Buy Right Now if you’d like to see an extended list and the methodology behind it.

5. Mineralys Therapeutics Inc. (NASDAQ:MLYS)

Potential Upside: 93.4%

During the last few trading sessions, Mineralys Therapeutics Inc. (NASDAQ:MLYS) has seen positive momentum. On June 4, Goldman Sachs analyst Richard Law reiterated a Buy rating on the stock and assigned a target price of $42.

Earlier on June 2, MLYS revised its agreement with Tanabe Pharma to gain full worldwide rights to lorundrostat without having to pay future royalties. Under this amendment, the company agreed to pay Tanabe a $200 million upfront cash payment and could make additional payments of up to $365 million if certain commercial targets are achieved. Moreover, the company secured a loan of up to $500 million from funds managed by Pharmakon Advisors. The financing will be provided in stages, with access to additional funds tied to the FDA approval of lorundrostat and the achievement of certain sales milestones. This loan will provide capital to support the company’s growth and commercialization plans. However, it also increases MLYS’s debt obligations, which could limit the company’s financial flexibility.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is a biopharmaceutical company that develops medicines to target diseases driven by dysregulated aldosterone. Its primary drug candidate is lorundrostat, which is used for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

4. Structure Therapeutics Inc. (NASDAQ:GPCR)

Potential Upside: 93.8%

On June 7, Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) and set a price target of $101. The firm’s price target implies an additional 95% upside from current levels.

In addition to Prakhar Agrawal, BMO Capital analyst Evan Seigerman reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5 and set a target price of $145. The analyst believes that the company’s most advanced weight-loss drug, aleniglipron, showed strong results in clinical trials. The data showed significant and sustained weight loss, along with a favorable safety profile with no major liver concerns. These positive results suggest aleniglipron could become one of the leading oral obesity treatments on the market.

In addition to weight loss, the drug showed benefits such as lowering blood pressure and reducing inflammation without causing a significant increase in heart rate. Evan Seigerman believes these results highlight the drug’s broader health benefits. As the demand for obesity treatment grows, aleniglipron has the potential to become an attractive option due to its oral administration and lower-cost alternative to injectables.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops and delivers novel oral small-molecule therapeutics. It treats various chronic diseases with unmet medical needs. The company was formerly known as ShouTi Inc. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

3. Vaxcyte Inc. (NASDAQ:PCVX)

Potential Upside: 96.2%

On June 18, Mizuho Securities analyst Salim Syed reiterated a Buy rating on Vaxcyte Inc. (NASDAQ:PCVX) with a price target of $163. The firm’s price target reflects a significant 180% upside from current levels.

Earlier on June 16, PCVX announced an update regarding its ongoing clinical study. The company is conducting an early-stage clinical trial of VAX-A1, a vaccine designed to protect against Group A strep infections. The study will evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy young adults. The trial is testing three different dose levels of the vaccine against a placebo. It is administered via muscle injection and is designed to support the immune system.

If the trial shows positive results, the vaccine could allow the company to enter a new market for preventing Group A strep infections. This could boost investor confidence in the company and support the stock’s valuation. However, disappointing results could increase concerns about the program and shift attention toward larger vaccine competitors such as Pfizer and GSK.

Vaxcyte Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company develops a variety of vaccines, and its major candidate is VAX-24. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. It was incorporated in 2013 and is headquartered in San Carlos, California.

2. Bitmine Immersion Technologies Inc. (NYSE:BMNR)

Potential Upside: 133.2%

On June 19, Bitmine Immersion Technologies Inc. (NYSE:BMNR) announced that it has declared a cash dividend of $0.1056 per share for holders of its 9.5% Series A Preferred Stock. The dividend will be paid in cash on July 10, 2026, to shareholders. This announcement reflects the company’s commitment to returning capital to its preferred shareholders. BMNR is expanding bitcoin mining into Ethereum treasury operations and staking infrastructure. Moreover, with the volatility and regulatory uncertainty surrounding digital asset markets, the company believes it is stable and can manage risk well.

Earlier on June 15, BMNR announced that its combined crypto holdings, cash, marketable securities, and moonshot assets reached $10.4 billion. As the company is shifting towards the Ethereum treasury, it now holds 5.62 million Ethereum worth approximately $9.7 billion. According to Chairman Tom Lee, Bitmine is now 93% of the way toward its goal of acquiring 5% of all Ethereum. He noted that AI systems that operate independently are creating more demand for neutral public blockchains like ETH.

Thomas Lee, Chairman of Bitmine, commented:

The best years for crypto remain ahead, in our view. Tokenization and the rapid progress in AI are expected to drive exponential demand growth for blockchain and decentralized crypto.

Bitmine Immersion Technologies Inc. (NYSE:BMNR) operates as a blockchain technology company. The company engages in ETH treasury operations. It also offers digital asset ecosystem services, including consulting/advisory and disciplined digital asset treasury management. The company was incorporated in 2019 and is based in Las Vegas, Nevada.

1.  Seabridge Gold Inc. (NYSE:SA)

Potential Upside: 149%

On June 8, Seabridge Gold Inc. (NYSE:SA) released its 2025 Sustainability Report. It outlined the company’s environmental, social, and ESG performance and progress across its mining projects in North America. As the company advances key projects, including KSM and the Bronson Corridor in British Columbia, the report highlighted the company’s efforts to align project development with sustainability goals. During 2025, the overall performance of SA was positive as the company reported a strong safety record, with an incident rate well below its target. It also made progress on connecting the KSM project to low-cost hydroelectric power.

These achievements could strengthen Seabridge’s reputation among the market competitors. The gold mining company’s focus on safety, renewable energy, and community engagement reflects its efforts to develop mining projects responsibly, which may increase investor confidence in the company. Moreover, such initiatives may also support future project approvals and development decisions.

Earlier, on June 3, Harrison Reynolds of RBC Capital maintained a Buy rating on Seabridge Gold Inc. (NYSE:SA) stock and set a price target of $71. This is the highest price target currently assigned to the stock by Wall Street analysts.

Seabridge Gold Inc. (NYSE:SA) engages in the acquisition and exploration of gold properties in North America. It explores for gold, silver, copper, and molybdenum deposits. The company was formerly known as Seabridge Resources Inc. and changed its name to Seabridge Gold Inc. in June 2002. It was founded in 1979 and is headquartered in Toronto, Canada.

READ NEXT: Iran Peace Deal Sends Oil Lower: Top 8 Travel Stocks to Buy Now and 10 AI Stocks That Are Surging.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.